ThromboGenics plans to absorb Belgian subsidiary Thromb-X
ThromboGenics NV announced that it has decided to absorb Thromb-X NV, a wholly-owned subsidiary of ThromboGenics NV. There shall be no issuance of new shares or cash payment upon this transaction. The transaction is expected to be approved at the next Extraordinary General Assembly in July 2007.
Thromb-X is based in Leuven, Belgium, and focuses on the research and development activities of the Group. This decision will enable ThomboGenics to streamline its corporate structure, consolidating its Belgian activities. There will be no impact on the company operations or financials.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.